1. What data in particular will be shared?
   Response - All of the individual participant data collected during the trial, after de-identification.
   


2. What additional supporting information will be shared?
   Response -  Study Protocol
   Response -  Statistical Analysis Plan
   Response - Clinical Study Report
   Response -  Analytic Code
   
   
3. Who will be able to view these files?
   Response - Anyone
   


4. For what types of analyses will this data be available?
   Response - Any purpose.
   


5. By what mechanism will data be made available?
   Response - Data are available indefinitely at (Link to be included www.dndeofficial.org/).
   


6. For how long will this data be available start date provided 01-12-2021 and end date provided 30-11-2026?
   Response - Beginning 3 months and ending 5 years following article publication.
   


7. Any URL or additional information regarding plan/policy for sharing IPD? 
   Additional Information - NIL

Acne vulgaris is a follicular disorder affecting susceptible pilo-sebaceous follicles, primarily of the face, neck, and upper trunk and characterized by both non-inflammatory and inflammatory lesions. It is estimated to affect 9.4% of the global population with 10-20% of some form of disorder, making it the 8th most prevalent disease worldwide and thus affect quality of life (QoL). Topical agents and synthetic retinoid isetretinoin often produce excellent results. But its use is highly regulated due to its potential for severe adverse events, primarily tetragenocity, depression, xerosis, cheilitis and occasional hypertriglyceridemia. Various complementary and alternative medicine (CAM) modalities have been introduced and found to have an important role in management of acne; however, their recommendation for treatment is limited by lack of large-scale studies and evidence about their efficacy and safety profile. In this double-blind, randomized, placebo-controlled trial at D. N. De Homoeopathic Medical College and Hospital, 40 patients suffering from acne vulgaris will be randomized to receive either individualized homeopathic medicines (verum; n=20) or identical-looking placebo (control; n=20). We aim to address the feasibility issues of conducting a definitive efficacy trial of individualized homoeopathy in treatment of acne vulgaris and to investigate whether there are any differences in outcomes between these two groups over 2 months of intervention. Global Acne Grading System (GAGS) and Cardiff Acne Disability Index (CADI) will be used as the primary and secondary outcome measures respectively. Feasibility issues will be checked and comparative analysis will be carried out to examine group differences, if any. Results will be published in scientific journals.